Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHYF) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to -$34.3 million.

  • Innate Pharma's Operating Expenses rose 1764.53% to -$34.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$232.5 million, marking a year-over-year decrease of 4016.22%. This contributed to the annual value of $76.6 million for FY2024, which is 417.63% down from last year.
  • Per Innate Pharma's latest filing, its Operating Expenses stood at -$34.3 million for Q2 2025, which was up 1764.53% from -$76.6 million recorded in Q4 2024.
  • Innate Pharma's 5-year Operating Expenses high stood at $8.7 million for Q2 2021, and its period low was -$83.0 million during Q4 2021.
  • Its 5-year average for Operating Expenses is -$43.4 million, with a median of -$41.6 million in 2024.
  • Per our database at Business Quant, Innate Pharma's Operating Expenses surged by 11726.94% in 2021 and then plummeted by 10565903.78% in 2023.
  • Over the past 5 years, Innate Pharma's Operating Expenses (Quarter) stood at -$83.0 million in 2021, then soared by 99.91% to -$75599.3 in 2022, then crashed by 105659.04% to -$80.0 million in 2023, then increased by 4.18% to -$76.6 million in 2024, then surged by 55.25% to -$34.3 million in 2025.
  • Its Operating Expenses stands at -$34.3 million for Q2 2025, versus -$76.6 million for Q4 2024 and -$41.6 million for Q2 2024.